Novartis Pharmaceuticals Canada Inc.
385 Bouchard Boulevard
Dorval
Quebec
H9S 1A9
Canada
Tel: 514-631-6775
38 articles about Novartis Pharmaceuticals Canada Inc.
-
Novartis Canada's statement on CADTH draft recommendations for LEQVIO (inclisiran)
3/21/2024
Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).
-
Mark Vineis appointed as the new Country President of Novartis Canada
12/5/2023
Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024.
-
PLUVICTO receives positive recommendations from CADTH and INESSS for progressive PSMA-positive metastatic castration-resistant prostate cancer
7/10/2023
Novartis Pharmaceuticals Canada Inc. is pleased to announce that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) and the Institut national d'excellence en santé et services sociaux (INESSS) have recommended PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection) for public reimbursement.
-
Novartis Canada launches new head office in the Health Innovation District of Montréal, featuring a unique environment to inspire co-creation, partnerships and continued healthcare innovation
5/18/2023
Novartis Pharmaceuticals Canada Inc. is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal.
-
Gene replacement therapy Luxturna® now reimbursed in Ontario for adult and pediatric patients with a rare form of inherited vision loss
3/1/2023
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Luxturna® is now funded by the Ontario government for the treatment of adults and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed mutations in both copies of the RPE65 gene and who have sufficient, viable retinal cells.
-
Novartis partners with network of secondary prevention clinics to redefine the standard of care for cardiovascular disease prevention and treatment in Ontario
2/7/2023
Novartis Pharmaceuticals Canada Inc. today announced a collaboration with health teams in Ontario to bring together a network of secondary prevention Nurse Practitioner (NP) enabled traditional and virtual cardiology clinics in select Ontario sites.
-
Health Canada approves (Pr)Tabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
6/8/2022
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has granted a Notice of Compliance with conditions for Tabrecta® for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 skipping alterations.
-
Novartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physicians
6/8/2022
The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice.
-
Ontario and Quebec become the first provinces to list Kesimpta (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS)
4/25/2022
Novartis Pharmaceuticals Canada Inc. is pleased to announce that PrKesimpta® (ofatumumab) is now covered under the Ontario Exceptional Access Program (EAP) and included on the Régie de l'assurance maladie du Québec (RAMQ) List of Medications as an Exceptional Medication for the treatment of adults living with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.
-
Beovu (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration
12/17/2021
Beovu ® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy.
-
Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
10/16/2021
Novartis Pharmaceuticals Canada Inc. applauds the government of Quebec's decision to provide public reimbursement for Zolgensma® under the Régie de l'assurance maladie du Québec for the treatment of children with SMA.
-
Novartis Pharmaceuticals Canada Inc. announces digital innovation partnership in multiple sclerosis with Innodem Neurosciences
10/5/2021
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce today a multi-year partnership agreement with Innodem Neurosciences to conduct a breakthrough clinical trial to help people living with multiple sclerosis.
-
Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
10/5/2021
Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
-
Novartis Canada launches the Biome Summit -- a catalyst to healthcare transformation and the future of care systems in Canada
8/26/2021
Novartis Pharmaceuticals Canada Inc., in partnership with C2 International is hosting the first ever Biome Summit in Canada.
-
Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease
4/29/2021
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still's disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
-
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah (tisagenlecleucel)
4/28/2021
Novartis Pharmaceuticals Canada Inc. is pleased to announce that two centres in Alberta have been certified in accordance with applicable requirements, making Kymriah® (tisagenlecleucel) available to certain leukemia and lymphoma patients.
-
Novartis' KISQALI (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
3/18/2021
KISQALI ® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners and the broadest spectrum of patients in two Phase III trials in advanced breast cancer .
-
Novartis' MONALEESA-7 KISQALI® (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
11/2/2020
KISQALI® is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.
-
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
8/13/2020
Approval is based on results from SOLAR-1, where PIQRAY® in combination with fulvestrant nearly doubled median progression-free survival (PFS) compared to fulvestrant alone
-
Canadian company AccessNow wins Novartis Innovation Prize for Assistive Tech
6/25/2020
Initiated in late 2019, the Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identified and encouraged technology ideas from all over the world with the aim to improve mobility, accessibility and daily life for people living with MS